- Home
- LDP vs PHAR Comparison
LDP vs PHAR Comparison
Compare LDP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- PHAR
- Stock Information
- Founded
- LDP 2012
- PHAR 1988
- Country
- LDP United States
- PHAR Netherlands
- Employees
- LDP N/A
- PHAR N/A
- Industry
- LDP Finance Companies
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- PHAR Health Care
- Exchange
- LDP Nasdaq
- PHAR Nasdaq
- Market Cap
- LDP 628.4M
- PHAR 1.0B
- IPO Year
- LDP N/A
- PHAR N/A
- Fundamental
- Price
- LDP $21.79
- PHAR $14.27
- Analyst Decision
- LDP
- PHAR Strong Buy
- Analyst Count
- LDP 0
- PHAR 3
- Target Price
- LDP N/A
- PHAR $30.00
- AVG Volume (30 Days)
- LDP 102.5K
- PHAR 12.8K
- Earning Date
- LDP 01-01-0001
- PHAR 10-23-2025
- Dividend Yield
- LDP 7.91%
- PHAR N/A
- EPS Growth
- LDP N/A
- PHAR N/A
- EPS
- LDP N/A
- PHAR N/A
- Revenue
- LDP N/A
- PHAR $339,836,000.00
- Revenue This Year
- LDP N/A
- PHAR $16.63
- Revenue Next Year
- LDP N/A
- PHAR $6.77
- P/E Ratio
- LDP N/A
- PHAR N/A
- Revenue Growth
- LDP N/A
- PHAR 22.44
- 52 Week Low
- LDP $16.16
- PHAR $7.31
- 52 Week High
- LDP $20.30
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- LDP 63.44
- PHAR 54.65
- Support Level
- LDP $21.46
- PHAR $13.63
- Resistance Level
- LDP $21.85
- PHAR $15.61
- Average True Range (ATR)
- LDP 0.14
- PHAR 0.93
- MACD
- LDP 0.02
- PHAR -0.13
- Stochastic Oscillator
- LDP 90.00
- PHAR 35.98
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.